BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20878241)

  • 1. Fusion expression and immunogenicity of Bordetella pertussis PTS1-FHA protein: implications for the vaccine development.
    Jinyong Z; Xiaoli Z; Weijun Z; Ying G; Gang G; Xuhu M; Quanming Z
    Mol Biol Rep; 2011 Mar; 38(3):1957-63. PubMed ID: 20878241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.
    Knight JB; Huang YY; Halperin SA; Anderson R; Morris A; Macmillan A; Jones T; Burt DS; Van Nest G; Lee SF
    Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purification and immunogenicity of a recombinant Bordetella pertussis S1S3FHA fusion protein expressed by Streptococcus gordonii.
    Lee SF; Halperin SA; Knight JB; Tait A
    Appl Environ Microbiol; 2002 Sep; 68(9):4253-8. PubMed ID: 12200273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal and systemic immune responses elicited by recombinant Lactococcus lactis expressing a fusion protein composed of pertussis toxin and filamentous hemagglutinin from Bordetella pertussis.
    Torkashvand A; Bahrami F; Adib M; Ajdary S
    Microb Pathog; 2018 Jul; 120():155-160. PubMed ID: 29738814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haemagglutination induced by Bordetella pertussis filamentous haemagglutinin adhesin (FHA) is inhibited by antibodies produced against FHA(430-873) fragment expressed in Lactobacillus casei.
    Colombi D; Oliveira ML; Campos IB; Monedero V; Pérez-Martinez G; Ho PL
    Curr Microbiol; 2006 Dec; 53(6):462-6. PubMed ID: 17106803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of safer pertussis DNA vaccine expressing non-toxic C180 polypeptide of pertussis toxin S1 subunit.
    Kamachi K; Arakawa Y
    Vaccine; 2007 Jan; 25(6):1000-6. PubMed ID: 17050047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restricted antibody response to Bordetella pertussis filamentous hemagglutinin induced by whole-cell and acellular pertussis vaccines.
    Asgarian-Omran H; Golara M; Abdolmaleki S; Navabi SS; Alipour H; Khoshnoodi J; Hemmati A; Zarei S; Jeddi-Tehrani M; Shokri F
    Infect Dis (Lond); 2016 Feb; 48(2):127-32. PubMed ID: 26439274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective activities in mice of monoclonal antibodies against pertussis toxin.
    Sato H; Sato Y
    Infect Immun; 1990 Oct; 58(10):3369-74. PubMed ID: 1698179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cloning and immunologic characterization of a truncated Bordetella bronchiseptica filamentous hemagglutinin fusion protein.
    Keil DJ; Burns EH; Kisker WR; Bemis D; Fenwick B
    Vaccine; 1999 Dec; 18(9-10):860-7. PubMed ID: 10580199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of Bordetella pertussis filamentous hemagglutinin with human TLR2: identification of the TLR2-binding domain.
    Asgarian-Omran H; Amirzargar AA; Zeerleder S; Mahdavi M; van Mierlo G; Solati S; Jeddi-Tehrani M; Rabbani H; Aarden L; Shokri F
    APMIS; 2015 Feb; 123(2):156-62. PubMed ID: 25353353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies produced against a fragment of filamentous haemagglutinin (FHA) of Bordetella pertussis are able to inhibit hemagglutination induced by the whole adhesin.
    Colombi D; Horton DS; Oliveira ML; Sakauchi MA; Ho PL
    FEMS Microbiol Lett; 2004 Nov; 240(1):41-7. PubMed ID: 15500977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction and characterization of single-chain variable fragment antibodies directed against the Bordetella pertussis surface adhesins filamentous hemagglutinin and pertactin.
    Hussein AH; Davis EM; Halperin SA; Lee SF
    Infect Immun; 2007 Nov; 75(11):5476-82. PubMed ID: 17724067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rapid ELISA-based method for screening Bordetella pertussis strain production of antigens included in current acellular pertussis vaccines.
    Barkoff AM; Guiso N; Guillot S; Xing D; Markey K; Berbers G; Mertsola J; He Q
    J Immunol Methods; 2014 Jun; 408():142-8. PubMed ID: 24925807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunodominant domains present on the Bordetella pertussis vaccine component filamentous hemagglutinin.
    Leininger E; Bowen S; Renauld-Mongénie G; Rouse JH; Menozzi FD; Locht C; Heron I; Brennan MJ
    J Infect Dis; 1997 Jun; 175(6):1423-31. PubMed ID: 9180182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of a three-component acellular pertussis vaccine administered at birth.
    Belloni C; De Silvestri A; Tinelli C; Avanzini MA; Marconi M; Strano F; Rondini G; Chirico G
    Pediatrics; 2003 May; 111(5 Pt 1):1042-5. PubMed ID: 12728086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum antibody response to B. pertussis Tn5 mutants, purified PT and FHA in two different mouse strains and passive protection in the murine intranasal infection model.
    Olander RM; Muotiala A; Karvonen M; Kuronen T; Runeberg-Nyman K
    Microb Pathog; 1990 Jan; 8(1):37-45. PubMed ID: 2159104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Humoral response to the injection of acellular Pertussis vaccine].
    Zakharova NS; Remova TN; Britsina MV; Shmeleva EI; Mertsalova NU; Zaĭtsev EM; Ozeretskovskaia MN; Bazhanova IG; Ermolova EV
    Zh Mikrobiol Epidemiol Immunobiol; 2001; (6):40-4. PubMed ID: 11881494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA vaccine encoding pertussis toxin S1 subunit induces protection against Bordetella pertussis in mice.
    Kamachi K; Konda T; Arakawa Y
    Vaccine; 2003 Nov; 21(31):4609-15. PubMed ID: 14575775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocyte-macrophage colony-stimulating factor DNA prime-protein boost strategy to enhance efficacy of a recombinant pertussis DNA vaccine.
    Li QT; Zhu YZ; Chu JY; Dong K; He P; Feng CY; Hu BY; Zhang SM; Guo XK
    Acta Pharmacol Sin; 2006 Nov; 27(11):1487-94. PubMed ID: 17049126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.